本帖最后由 老马 于 2013-3-13 13:43 编辑
9 S8 ?. j- L; ~* Y% Z( k; p: R8 R& {' i
健择(吉西他滨)+顺铂+阿瓦斯汀" b, t3 c9 T( V( b/ O1 @7 l
Gemzar +Cisplatin + Avastin, J, w- N7 D+ j" M6 ?8 y
http://annonc.oxfordjournals.org/content/21/9/1804.full* v d- ^- { K4 ]% N) F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' x5 O1 O5 p' W# r" M8 b' f" MPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. # y( B" v6 b# n9 `9 @& H
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
v+ X: I5 G1 Z7 O0 i
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 350)
. }3 [0 X" K+ \$ f6 p华为网盘附件:: ]7 L/ f# ]) k( F$ n1 c; |4 [, R! r
【华为网盘】ava.JPG
( C- U2 M2 a% B |